One of the standouts of today's afternoon trading session has been Sarepta Therapeutics, which logged a -6.4% drop and underperformed the S&P 500 by -6.0%. The Pharmaceutical stock is now trading at ...

In this article, we are going to take a look at where Sarepta Therapeutics, Inc. (NASDAQ:SRPT) stands against the other stocks. Jim Cramer, the host of Mad Money, recently expressed his concerns ...

Nisa Investment Advisors LLC grew its position in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Free Report) by 23.1% in the fourth quarter, according to its most recent filing with the SEC.

RBC Capital analyst Brian Abrahams says shares of Sarepta (SRPT) could be trading lower today on an FDA database update that included am Elevidys patient death, which occurred in November in a ...

Sarepta Therapeutics (NASDAQ:SRPT), a biotechnology company specializing in precision genetic medicines for rare diseases with a market capitalization of $11.2 billion, stands at a critical ...

Sarepta's third-quarter results for 2024 exceeded expectations, with total revenue reaching approximately $430 million, surpassing the consensus estimate of $400 million. The company's trailing twelve ...

Shares of Sarepta (SRPT) are down this morning, potentially due to the latest FDA Adverse Event Reporting System update on Elevidys, which included a patient death from November in a patient who ...